Compare · ARVN vs AZN
ARVN vs AZN
Side-by-side comparison of Arvinas Inc. (ARVN) and AstraZeneca PLC (AZN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARVN and AZN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $555.04B, about 1232.4x ARVN ($450.4M).
- Over the past year, ARVN is down 8.8% and AZN is down 5.0% - AZN leads by 3.8 points.
- AZN has been more active in the news (21 items in the past 4 weeks vs 4 for ARVN).
- Both have 25 recent analyst ratings on file.
- Company
- Arvinas Inc.
- AstraZeneca PLC
- Price
- $7.00-2.98%
- $178.80-2.43%
- Market cap
- $450.4M
- $555.04B
- 1M return
- -27.74%
- -1.69%
- 1Y return
- -8.80%
- -5.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- 2026
- News (4w)
- 4
- 21
- Recent ratings
- 25
- 25
Arvinas Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest ARVN
- Arvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's Disease
- Arvinas Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Arvinas to Present at Jefferies Global Healthcare Conference
- President and CEO Teel Randy sold $19,962 worth of shares (2,209 units at $9.04), decreasing direct ownership by 0.77% to 285,009 units (SEC Form 4) (tax liability)
- Chief Financial Officer Saik Andrew sold $110,693 worth of shares (11,139 units at $9.94), decreasing direct ownership by 5% to 193,128 units (SEC Form 4) to satisfy withholding obligation
- Chief Scientific Officer Cacace Angela M sold $95,965 worth of shares (9,657 units at $9.94), decreasing direct ownership by 5% to 182,966 units (SEC Form 4) to cover withholding tax
- VP, Chief Accounting Officer Loomis David K sold $19,070 worth of shares (1,919 units at $9.94), decreasing direct ownership by 5% to 40,193 units (SEC Form 4) to satisfy withholding tax
- Chief Medical Officer Berkowitz Noah sold $110,385 worth of shares (11,108 units at $9.94), decreasing direct ownership by 5% to 191,395 units (SEC Form 4) (withholding obligation)
- President and CEO Teel Randy sold $95,965 worth of shares (9,657 units at $9.94), decreasing direct ownership by 3% to 287,218 units (SEC Form 4) (withholding tax)
- Arvinas Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest AZN
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC